Personalized treatment and telemedicine support for Multiple System Atrophy
Medical Decision Making in Multiple System Atrophy: Developing Personalized Best Medical Care with Integrated Telemedicine and Mobile Palliative Care for Individuals with Multiple System Atrophy
This study is testing if a personalized treatment plan with regular telemedicine support can improve the quality of life for people with Multiple System Atrophy and their caregivers.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 92 (estimated) |
| Ages | 30 Years and up |
| Sex | All |
| Sponsor | Medical University Innsbruck Academic / other |
| Locations | 1 site (Innsbruck, Austria) |
| Trial ID | NCT06072105 on ClinicalTrials.gov |
What this trial studies
This clinical study evaluates the effects of a personalized symptomatic treatment plan combined with monthly telemedicine and mobile palliative care interventions for individuals diagnosed with Multiple System Atrophy (MSA) and their informal caregivers. A total of 46 patients will receive a tailored therapeutic plan that includes medical treatment, physiotherapy, psychological support, and social work assistance. Participants will be assessed at baseline and re-evaluated at 6, 12, and 18 months to measure changes in quality of life. The study aims to enhance the support provided to patients and caregivers throughout the progression of the disease.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 30 and older diagnosed with clinically probable or established MSA who can comply with study procedures.
Not a fit: Patients who do not meet the inclusion criteria or have a life expectancy of less than 24 months may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve the quality of life for MSA patients and their caregivers.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in improving patient outcomes through personalized care and telemedicine.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria For individuals with MSA: * Age ≥30 years at the time of consent; * Diagnosed with clinically probable or clinically established MSA according to the current MDS MSA criteria (1); * Life-expectancy of at least 24 months as assessed by the investigator at the time of consent; * Understands and agrees to comply with the study procedures and provides written informed consent (Note: a legal representative may NOT provide consent on behalf of the subject); * Signed and dated informed consent document; * Fluency in German; * If not able to walk or stand without assistance/support at the time of consent, the participant lives in Tyrol or in another Austrian Region with available mobile palliative care. For informal caregivers: * Informal caregiver (i.e. person not receiving payment for his/her caregiving) of an individual with MSA recruited in the present study; * Life-expectancy of at least 24 months as assessed by the investigator at the time of consent; * Age≥ 18 years at the time of consent; * Understands and agrees to provide information as outlined in the study protocol and to engage in semi-structured online interviews; * Provides signed and dated written informed consent; * Full legal capacity; * Fluency in German. Exclusion Criteria For individuals with MSA * Participation in an interventional clinical study at screening and throughout the study that would interfere with the MeDeMSA Care personalized treatment plan or would not permit telemedicine and mobile palliative care strategies; * Charlson comorbidity index \>4 at the time of consent; * Other major underlying medical conditions that may confound interpretation of study results as assessed by the investigator.
Where this trial is running
Innsbruck, Austria
- Innsbruck Medical University — Innsbruck, Austria, Austria (Recruiting)
Study contacts
- Principal investigator: Alessandra Fanciulli, MD PhD — Medical University Innsbruck
- Study coordinator: Alessandra Fanciulli, MD PhD
- Email: alessandra.fanciulli@i-med.ac.at
- Phone: +4351250483238
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.